▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Oct 15, 2016 by Todd Campbell

What's Up With Medicare Advantage in 2017?

Here's what you need to know about Medicare Advantage during this year's Medicare open enrollment season.

GettyImages-91685233

Oct 15, 2016 by Todd Campbell, Dan Caplinger, and Jamal Carnette, CFA

Looking to Beat Inflation? Check Out These 3 Stocks

The risk of inflation to stocks can be significant, and that has some of The Motley Fool's top contributors considering what stocks could benefit if input prices start surging higher.

market crash image023 getty 1

Oct 14, 2016 by Todd Campbell

Why Ariad Pharmaceuticals Tumbled 14.8% Today

Worry over mounting political scrutiny of its pricing of Iclusig led investors to head for the exits today.

GettyImages-519336818

Oct 14, 2016 by Todd Campbell

Is Opko Health On the Cusp of a Big Year?

Royalties from Varubi, sales from Rayaldee, and a potential new human growth hormone could make 2017 a big year for this company.

marijuana medical 1 GettyImages-483300738

Oct 14, 2016 by Todd Campbell

2 Marijuana Stocks That Are Going in Opposite Directions

While Insys Therapeutics' past continues to haunt it, GW Pharmaceuticals' marijuana research is paying off.

Oct 14, 2016 by Todd Campbell

What Would Trump or Clinton Do to Healthcare Next Year?

Donald Trump and Hillary Clinton have very different views on how to fix America's ailing healthcare system. Here's what each of these candidates plans to do if elected president.

GettyImages-507404698

Oct 14, 2016 by Todd Campbell

3 Big-Cap Stocks That Are Growing Again

Pfizer, Inc. Microsoft Corp, and Boston Scientific are back on their feet and growing again and that may make now a good time to buy them in portfolios.

Oct 13, 2016 by Todd Campbell

How Risky Is Merrimack Pharmaceuticals Stock?

Merrimack Pharmaceuticals has key catalysts on deck that could move shares significantly in the coming year.

Oct 12, 2016 by Todd Campbell and Kristine Harjes

This Remarkable Device Revolutionizes Diabetes Treatment

The approval of Medtronic's artificial pancreas system ushers in a new era for type 1 diabetes treatment. Plus, a new study includes some surprising revelations regarding medical marijuana.

Oct 11, 2016 by Todd Campbell

Why Sarepta Therapeutics Skyrocketed 131% in September

The official approval of the company's therapy for Duchenne muscular dystrophy has investors seeing green.

rocket ship GettyImages-515682468

Oct 10, 2016 by Todd Campbell

Why Tesaro, Inc. Is Skyrocketing 20% Today

Investors are cheering following the release of late-stage trial results for the company's ovarian cancer drug.

warren-buffett-buys-apple-stock_large

Oct 10, 2016 by Todd Campbell, Daniel Miller, and Timothy Green

The Next Stock Warren Buffett May Sell

Just because the Oracle of Omaha prefers a holding period of "forever," doesn't mean that he never sells stocks.

rocket ship GettyImages-515682468

Oct 10, 2016 by Todd Campbell

Why Array BioPharma Skyrocketed 91% in September

News that the FDA will weigh in with an approval decision next summer for the company's most advanced drug was followed up later in the month by positive data from an important late-stage study. That one-two combination of positive news sparked investor enthusiasm and sent shares soaring.

dividend-income-business-man-with-giant-magnent-attracting-money_large

Oct 9, 2016 by Todd Campbell

3 Cheap Dividend Stocks That Could Rally Higher

Investors hunting for income-paying stocks to add to their portfolios might want to consider investing in these three companies, each of which has catalysts that could result in bigger dividend payments down the road.

approval stamp GettyImages-483943680

Oct 9, 2016 by Todd Campbell

3 Cancer Drugs That Could Get an FDA OK Next Year

Cancer drug development is costly and fraught with failure, but these three companies have successfully navigated clinical trials and as a result, each has a chance at winning FDA approval of their drugs in 2017.

Oct 8, 2016 by Todd Campbell

The Big Reason You Shouldn't Give Up on Big-Cap Biotech

Big-cap biotechs Gilead Sciences, Celgene, and Regeneron have lost ground in 2016, but each has catalysts coming that could drive future revenue and profit growth.

market crash image getty 2

Oct 7, 2016 by Todd Campbell

Why Clovis Oncology Shares Are Falling 14.5% Today

Updated study results supporting the company's FDA application for approval of rucaparib reveal a safety profile that's causing concern among investors.

marijuana medical 1 GettyImages-483300738

Oct 7, 2016 by Todd Campbell

These States Could Legalize Marijuana Next Month

Voters in nine states, including California, Florida, and Massachusetts, will decide whether to approve either recreational or medical marijuana ballot measures in November.

Oct 6, 2016 by Todd Campbell

Why Opko Health Shares Rallied 14% in September

Results from a late-stage trial of Opko Health Inc.'s long-lasting human growth hormone are expected later this year.

Oct 6, 2016 by Todd Campbell

Why This Marijuana Stock Crashed 18% in September

As CEO President & CEO Dr. John Kapoor prepares to leave, Insys Therapeutics stock got hammered last month.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services